Iconix Brand Group, Inc. 是一間品牌管理公司,在美國及國際上擁有並授權一系列消費品牌。公司總部位於紐約州紐約市。
財務指標
營業收入
2026-06-30
$4.18M
2026-03-31
$3.64M
2025-12-31
$3.53M
2025-09-30
$4.17M
營業支出
2026-06-30
$1.9M
2026-03-31
$1.15M
2025-12-31
$608K
2025-09-30
$505K
淨利潤
2026-06-30
-$784K
2026-03-31
$417K
2025-12-31
-$581K
2025-09-30
$78K
淨利潤率
2026-06-30
-18.72%
2026-03-31
11.43%
2025-12-31
-16.44%
2025-09-30
1.86%
每股收益
2026-06-30
$-0.62
2026-03-31
$-0.33
2025-12-31
$-14.71
2025-09-30
$-2.25
息稅折舊攤銷前利潤
2026-06-30
$982K
2026-03-31
$2.19M
2025-12-31
$1.01M
2025-09-30
$2.28M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$4.18M
$3.64M
$3.53M
$4.17M
營業支出
$1.9M
$1.15M
$608K
$505K
淨利潤
-$784K
$417K
-$581K
$78K
淨利潤率
-18.72%
11.43%
-16.44%
1.86%
每股收益
$-0.62
$-0.33
$-14.71
$-2.25
息稅折舊攤銷前利潤
$982K
$2.19M
$1.01M
$2.28M
有效稅率
--
--
--
--
常見問題
ICON plc is a global contract research organization (CRO) that provides clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. It helps companies design, manage, and analyze clinical trials, offering services such as clinical monitoring, data management, biostatistics, and regulatory consulting. The company operates in numerous countries and supports drug development from early-phase studies through post-approval research.
ICON operates in the life sciences and healthcare services sector, specifically within the contract research organization (CRO) industry. CROs provide outsourced clinical trial and drug development services to pharmaceutical, biotechnology, and medical device companies. This industry is characterized by long-term contracts, regulatory requirements, and reliance on research and development spending by healthcare firms.
ICON's stock price can be influenced by changes in pharmaceutical and biotech R&D spending, clinical trial wins or cancellations, contract backlog, and overall demand for outsourced research services. Broader factors include regulatory changes, global economic conditions, interest rates, and competition from other CROs. Additionally, trial outcomes, partnership announcements, and quarterly earnings results can impact investor sentiment and the stock's performance.
Key risks for ICON include dependence on the pharmaceutical and biotech industries, which may reduce R&D spending during downturns. The company faces intense competition from other CROs, pricing pressure, and potential project cancellations or delays. Regulatory changes, geopolitical instability, and currency fluctuations can also affect operations. Additionally, client concentration and the ability to recruit and retain skilled staff are important considerations for investors.
Start by reviewing ICON's investor relations website for annual reports, quarterly filings, and press releases. Financial data platforms provide key metrics like revenue, earnings, and valuation ratios. Analyst reports and industry publications can offer context on the CRO sector. For current stock price, market cap, and other live data, refer to the latest ICON data displayed on this page.
ICON does not currently pay a regular dividend. The company retains earnings to fund growth initiatives, acquisitions, and research and development. Investors seeking income may want to consider this when evaluating ICON. For the most up-to-date dividend policy, check the latest ICON data and official company announcements.